ABPI Guidelines for Phase 1 Clinical Trials (PDF
ABPI Guidelines for Phase 1 Clinical Trials (PDF
ABPI Guidelines for Phase 1 Clinical Trials (PDF
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Certificate of analysis - a document of the identity, purity and strength of an IMP.<br />
Chief investigator - leads a group of principal investigators.<br />
<strong>Clinical</strong> (human) pharmacology - the scientific basis of phase 1 trials.<br />
<strong>Clinical</strong> Trial Authorisation (CTA) - sponsors must obtain a CTA from the MHRA be<strong>for</strong>e they can start a trial of an IMP.<br />
<strong>Clinical</strong> trial (study) - tests the safety and activities of an IMP in humans.<br />
<strong>Clinical</strong> trial (study) report - includes all the results of a trial and an analysis and clinical interpretation of them.<br />
Comparator - a marketed medicine, a placebo, or another preparation of an IMP used <strong>for</strong> comparison in a trial.<br />
Complement system - many small plasma proteins that work together to clear pathogens, such as bacteria, and promote<br />
healing.<br />
Compliance - meeting the relevant requirements <strong>for</strong> a trial-related function.<br />
Confidentiality - making sure that only authorised people see a sponsor's proprietary in<strong>for</strong>mation or know a trial subject's<br />
identity.<br />
Concentration-response curve - relationship between concentration of the IMP in blood or tissues and its effect.<br />
Continuing Professional Development (CPD) - process by which physicians keep up-to-date, develop new skills and<br />
maintain a high standard of professional practice.<br />
Contract - a written, dated and signed agreement among the parties to a trial, such as the sponsor, investigator and CRO,<br />
that sets out the duties and responsibilities, including financial, of each party (the protocol can be the basis of the contract).<br />
Contract research organisation (CRO) - a commercial, academic or other type of organisation that may carry out the<br />
sponsor's trial-related duties and functions.<br />
Control of Substances Hazardous to Health (COSHH) - regulations to protect workers against any substance in the<br />
workplace that might damage their health.<br />
Curriculum vitae (CV) - written details of the researchers' qualifications and experience that enable sponsors, MHRA or<br />
REC to assess the eligibility of the researchers to do a trial.<br />
Cyclotron - produces radioactive isotopes of short half-life <strong>for</strong> research or diagnostic imaging.<br />
Cytokine - small proteins produced by cells, mainly white blood cells, in response to an immune stimulus. They mediate<br />
and regulate immunity and inflammation.<br />
Cytokine storm - uncontrolled release of cytokines which react with immune cells. A cytokine storm damages tissues and<br />
organs, which may be fatal.<br />
Data Protection Act - legislation to give people the right of control of personal in<strong>for</strong>mation that is held about them.<br />
Declaration of Helsinki - guidelines of the World Medical Association that protect the rights, safety and well-being of<br />
subjects who take part in clinical trials, and are revised every four years - Directive 2001/20/EC is based on the 1996<br />
version.<br />
Delayed hypersensitivity reaction - a harmful immune response caused by re-exposure to a protein to which the body has<br />
become sensitive as a result of a previous exposure.<br />
Deoxyribonucleic acid (DNA - the substance in cells that carries the genetic code <strong>for</strong> the individual.<br />
Diploma in Pharmaceutical Medicine (Dip Pharm Med) - a qualification in pharmaceutical medicine awarded by the<br />
Faculty of Pharmaceutical Medicine.<br />
Diploma in Human Pharmacology (DHP) - a qualification <strong>for</strong> principal investigators <strong>for</strong> phase 1 trials to be awarded by the<br />
Faculty of Pharmaceutical Medicine.<br />
Direct access - permission to examine, analyse, verify and reproduce the relevant records and reports of a clinical trial.<br />
Documentation - the process of creating records, in a written, magnetic, optical or other <strong>for</strong>m, that describes the methods<br />
and conduct of the study, factors affecting it, and the action taken. Records include the protocol and any amendments,<br />
copies of submissions and approvals from the MHRA and REC, curricula vitae, in<strong>for</strong>mation and consent <strong>for</strong>ms, monitor's<br />
reports, audit certificates, relevant letters, reference ranges, raw data, completed CRF and the final study report.<br />
Dose - the amount of an IMP given to the trial subject on one or more occasions (single- or multiple-dose). A dose may be<br />
one or more tablets, capsules, injections or other <strong>for</strong>m of the IMP.<br />
Dose-response curve - relationship between doses of an IMP and their effect.<br />
Efficacy - whether an IMP is effective.<br />
Endoscopy - looking into parts of the body - such as the stomach and windpipes - with an endoscope, a thin fibre-optic<br />
telescope with a light at the end.<br />
© Association of the British Pharmaceutical Industry 2007<br />
44